Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3 USD | -1.32% | -1.64% | -27.54% |
May. 08 | Transcript : Relmada Therapeutics, Inc., Q1 2024 Earnings Call, May 08, 2024 | |
May. 08 | Relmada Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 90.52M |
---|---|---|---|---|---|
Net income 2024 * | -102M | Net income 2025 * | -115M | EV / Sales 2024 * | - |
Net cash position 2024 * | 159M | Net cash position 2025 * | 89.3M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.99
x | P/E ratio 2025 * |
-1.22
x | Employees | 20 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.96% |
Latest transcript on Relmada Therapeutics, Inc.
1 day | -1.32% | ||
1 week | -1.64% | ||
1 month | -17.58% | ||
3 months | -51.02% | ||
6 months | +21.46% | ||
Current year | -27.54% |
Managers | Title | Age | Since |
---|---|---|---|
Paolo Manfredi
FOU | Founder | 62 | 12-05-30 |
Sergio Traversa
CEO | Chief Executive Officer | 63 | - |
Maged Shenouda
DFI | Director of Finance/CFO | 59 | 15-11-11 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 78 | 15-07-13 | |
Sergio Traversa
CEO | Chief Executive Officer | 63 | - |
Maged Shenouda
DFI | Director of Finance/CFO | 59 | 15-11-11 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.10% | 0 M€ | 0.00% | - | |
0.03% | 430 M€ | -.--% | ||
0.00% | 234 M€ | +8.48% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 3 | -1.32% | 63,626 |
24-05-30 | 3.04 | +3.75% | 129,478 |
24-05-29 | 2.93 | -0.68% | 26,454 |
24-05-28 | 2.95 | -3.28% | 65,341 |
24-05-24 | 3.05 | -1.93% | 92,014 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-27.54% | 90.52M | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- RLMD Stock